Navigation Links
FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
Date:3/3/2009

- Agency Supports Company's Production and Clinical and Preclinical Plans for DXL625 -

- Live Teleconference Scheduled with Leadership and Scientific Team for March 04, 2009 -

BRITISH COLUMBIA, Canada March 3 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing. At the Pre-IND meeting, FDA supported InNexus' current manufacturing plans stating that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus. FDA also reviewed completed animal testing and recommended a more expeditious design for the final animal studies to set the stage for human studies. Per these recommendations, InNexus foresees no regulatory impediment to the initiation of human clinical studies in early 2010.

"We are pleased to announce the completion of our pre-IND meeting with the FDA," said Dr. Jur Strobos, Vice President of Clinical & Regulatory Affairs of InNexus. "We appreciate the thorough review and clear support from FDA for our product development plan. Their review was detailed and comprehensive. As a result, we are particularly pleased that we have affirmation of a clear, simple, and rapid path for DXL625 use in human Phase I trials. Additional pre-clinical testing and analysis will be conducted over the coming months to move us along this path
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
3. NxStage Medical Provides Update on Medisystems Acquisition
4. VaxGen Files 2006 Financial Statements and Provides Cash Update
5. Signalife Provides Corporate Update
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
8. SGX Provides Update on BCR-ABL Collaboration
9. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 “Rapid technological advances ... the U.S., increasing unemployment, depressing American consumer spending ... is a Catch 22—we need automated manufacturing if ... fewer jobs,” says economist and corporate relocation expert ... Top 10 Pro-Business States for 2014, co-published with ...
(Date:7/31/2014)... Sales Horizons, a leader in sales training, today ... – Mastering the Complex Sale – to ... proven sales training programs used by thousands of salespeople ... sales training course is available to every salesperson as ... customers, like technical support, engineers, clinical support, and IT ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Sales Horizons, ... launch of blended sales training programs for companies engaged ... training programs used by thousands of salespeople over 25 ... sales training program can be customized to address the ... The blended sales training program consists of ...
Breaking Biology Technology:ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3
... 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... has been granted,U.S. Patent 7,374,752 entitled "Reovirus ... claims cover pharmaceutical compositions,which comprise various recombinant ... with additional patent protection for,reovirus compositions in ...
... ... Annual Meeting, ... with asthma not adequately controlled on the inhaled,corticosteroid fluticasone propionate ... the equivalent dose of,FP combined with salmeterol administered as Advair ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... Senior Vice President and Chief Medical Officer. Dr. ... and registration of cancer,therapeutics and has had a ... clinical pharmacologist, most notably at Novartis. Dr. Cohen,joins ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS 2Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS 3Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 2Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 3Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 4
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... decisions about what they eat, the Food and Drug ... the Nutrition Facts label found on nearly every food ... & Engineering News (C&EN), the weekly news magazine ... and the fight that has ensued. , Britt ... while the Nutrition Facts label has remained largely the ...
(Date:7/30/2014)... Brembs, professor of neurogenetics at the Institute of Zoology, ... readers and reviewers to run the underlying code within ... forward for scientific publishing, by demonstrating a completely novel ... , Figure 3 in fact doesn,t really exist. The ... F1000Research , and the figure is generated ,on the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... coastal habitats may release as much as 1 billion tons ... higher than previously reported, according to a new Duke led ... , the analysis provides the most comprehensive estimate of global ... date: 0.15 to 1.2 billion tons. It suggests there is ...
... September 6, 2012The naturally occurring cytokine interleukin-18, or IL-18, ... implicated in serious inflammatory diseases for which the prognosis ... Therapies targeting IL-18 could prove effective against inflammatory diseases ... pulmonary disease (COPD), as described in a review article ...
... release is available in Spanish . ... (ICCAT) is to invest 1.5 million euros in two research ... 2012 by AZTI-Tecnalia, the technological centre specialised in marine and ... the first project, the consortium co-ordinated by AZTI-Tecnalia will capture, ...
Cached Biology News:Destroyed coastal habitats produce significant greenhouse gas 2Promising new drug target for inflammatory lung diseases 2AZTI-Tecnalia leads 2 research projects on bluefin tuna with 1.5 million euros investment 2
... Serum is obtained from ... from healthy, fasted donors. The ... any way and are maintained ... Total Protein Concentration : ...
Hamster serum...
... Captiva 96-well Filter Plates are offered in ... 0.45 um depth filter plates are ideal ... analysis. Filtration is simple, versatile, and necessary ... The Captiva 10 um glass fiber and ...
... cDNA Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Biology Products: